Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Donor-specific transfusion.

Y Iwaki, P I Terasaki

    Clinical Transplants
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Donor-specific transfusions (DST) significantly improved one-year graft survival rates in living donor kidney transplants compared to non-DST. DST demonstrated higher graft survival across various donor types, particularly with parental donors at three years.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Landsteiner Award. HLA epitope matching.

    Transfusion·1992
    Same author

    HLA matching effect on five-year graft survival and half-life in the cyclosporine era.

    Kidney international. Supplement·1992
    Same author

    Prolongation of second heart transplants in rats.

    Transplantation·1992
    Same author

    Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. The UNOS Scientific Renal Transplant Registry.

    The New England journal of medicine·1992
    Same author

    Effect of mismatching serologically defined residues on kidney transplant survival.

    Transplantation proceedings·1992
    Same author

    Beneficial effect of sharing six-antigen-matched cadaver kidneys in the United States.

    Transplantation proceedings·1992
    Same journal

    Clinical Relevance of Donor-Specific IgM Antibodies in HLA Incompatible Renal Transplantation: A Retrospective Single-Center Study.

    Clinical transplants·2017
    Same journal

    Influenza Immunization and the Generation of Anti-HLA and Anti-MICA Antibodies in Patients with Renal Failure and in Kidney Transplant Recipients.

    Clinical transplants·2017
    Same journal

    From Accurate Assessment of Anti-HLA Antibody MFI to Complement-Binding Assays.

    Clinical transplants·2017
    Same journal

    Post-transplant Desensitization for Deceased Donor Kidney Transplant Recipients: A Single Center Experience.

    Clinical transplants·2017
    Same journal

    Acute Rejection in 6-Antigen HLA-Matched Kidney Transplant Recipients: Risk Factors and Outcomes from the Wisconsin Allograft Recipient Database (WisARD).

    Clinical transplants·2017
    Same journal

    C1q Donor-Specific Antibody Associates with Post-transplant Biopsy Findings in Highly- Sensitized Kidney Transplant Recipients.

    Clinical transplants·2017
    See all related articles

    Area of Science:

    • Nephrology
    • Immunology
    • Transplantation

    Background:

    • Donor-specific transfusions (DST) have been utilized in living donor kidney transplantation since 1982.
    • Approximately 25% of living donor graft recipients received DST.
    • The impact of DST on graft survival across different donor types requires detailed analysis.

    Purpose of the Study:

    • To evaluate the efficacy of DST in improving graft survival in living donor kidney transplantation.
    • To compare graft survival rates between DST and non-DST recipients.
    • To assess the influence of donor type and transfusion protocols on graft survival.

    Main Methods:

    • Retrospective analysis of living donor kidney transplant recipients treated with DST since 1982.
    • Comparison of one-year and three-year graft survival rates based on donor type (HLA-identical sibling, parental, offspring, haplotype-mismatched sibling) and transfusion status.

    Related Experiment Videos

  • Evaluation of the effect of cyclosporine treatment on graft survival in different donor and transfusion groups.

    • Main Results:

    • One-year graft survival with DST was high: 95% (HLA-identical siblings), 86% (parental donors), 92% (offspring), 87% (one-haplotype different siblings), and 85% (zero-haplotype different siblings).
    • DST rates were 2-11% higher than non-DST transplants.
    • At 3 years, parental donor transplants with >3 DST showed 82% survival, significantly higher than nontransfused grafts (63%).
    • Randomly transfused patients had a 90% 3-year survival compared to 79% in non-transfused patients for DST HLA-identical sibling grafts.
    • Cyclosporine improved survival in zero-transfusion parental donor grafts (73% to 85% at 1 year) and slightly improved sibling/HLA-identical donor grafts.

    Conclusions:

    • DST is associated with improved short-term and long-term graft survival in living donor kidney transplantation across various donor types.
    • Multiple DST and random transfusions appear beneficial, especially in parental donor and HLA-identical sibling donor grafts.
    • Cyclosporine's benefit is most pronounced in specific subgroups, suggesting a complex interplay between transfusion protocols and immunosuppression.